NCT03516123 is a Phase 1 clinical trial of CS3006 in Solid Tumor, Adult, sponsored by CStone Pharmaceuticals.

Who is sponsoring NCT03516123?

NCT03516123 is sponsored by CStone Pharmaceuticals.

What drugs are being tested in NCT03516123?

Interventions in NCT03516123: CS3006.

What condition does NCT03516123 study?

NCT03516123 studies Solid Tumor, Adult.

Is NCT03516123 still recruiting?

NCT03516123 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT03516123

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors

Completed Phase 1 Last updated 19 September 2024

What this trial tests

Phase 1 trial testing CS3006 in Solid Tumor, Adult in 18 participants. Completed in 18 June 2020.

Timeline

14 June 2018

Primary endpoint
18 June 2020

18 June 2020

Quick facts

Lead sponsor	CStone Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	14 June 2018
Primary completion	18 June 2020
Estimated completion	18 June 2020
Sites	1 location across Australia

Drugs / interventions tested

CS3006 — full drug profile →

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

CStone Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open label, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.
Yuan J, Dong X, Yap J, Hu J. · · 2020 · cited 388× · PMID 32807225 · DOI 10.1186/s13045-020-00949-4
Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R, Galvin R, Watson AL, Largaespada DA, et al · · 2021 · cited 19× · PMID 33721151 · DOI 10.1007/s11912-021-01032-y

Verify or expand the search:

Other trials of CS3006

Trials testing the same drug.

NCT03736850 — Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors · Phase 1 · completed

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other CStone Pharmaceuticals trials

Trials by the same sponsor.

NCT05381753 — Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World · completed
NCT05279300 — A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas · Phase 1 · recruiting
NCT04421352 — Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients · Phase 1 · completed
NCT04233060 — A Study of CS3005 in Advanced Solid Tumors · Phase 1 · completed
NCT04162301 — A Study of CS3002 in Subjects With Advanced Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03516123 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CStone Pharmaceuticals
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03516123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing